Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
These findings suggest that a PHID cutoff of 0.91 improves the selection of patients with elevated prostate-specific antigen who are referred for prostate biopsy, and potentially in patients with PI-RADS 1-2 lesions.
Authors
- Shayan Smani (ORCID: https://orcid.org/0000-0002-3456-2023)
- Mursal Gardezi (ORCID: https://orcid.org/0000-0003-2188-3167)
- Soum D. Lokeshwar (ORCID: https://orcid.org/0000-0002-5260-766X)
- Benjamin Press (ORCID: https://orcid.org/0000-0001-6387-3093)
- Lindsey T Webb (ORCID: https://orcid.org/0009-0006-5003-7049)
- Olamide Olawoyin (ORCID: https://orcid.org/0000-0002-9116-0557)
- Michael Leapman (ORCID: https://orcid.org/0000-0002-0727-7614)
- Ghazal Khajir (ORCID: https://orcid.org/0009-0008-7992-5351)
- Syed N. Rahman (ORCID: https://orcid.org/0000-0002-2646-6250)
- Preston C. Sprenkle (ORCID: https://orcid.org/0000-0003-0502-9294)
Institutions
- Yale University (US)
Publication Details
- Journal
- Exploration of Targeted Anti-tumor Therapy
- Published
- 2024-09-13
- DOI
- https://doi.org/10.37349/etat.2024.00269
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42